GlobeNewsWire
15 Jun 2026, 16:46 UTC · 14w ago
Verdict
Headline leans bearish. We score NMRA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Neumora Therapeutics' Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on primary or key secondary endpoints.
So whatClinical trial failure for a lead asset in a major indication typically leads to a severe loss of valuation for biotech companies.
More negative than 99% of claims this week
Neumora Therapeutics is discontinuing the development of navacaprant and reducing its workforce by approximately 35%.
So whatThe abandonment of the drug and significant layoffs signal a major strategic setback and a loss of operational scale.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 98% of claims this week
Holzer & Holzer, LLC is investigating whether Neumora Therapeutics complied with federal securities laws following the stock price drop.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company failed Phase 3 clinical trials, is discontinuing a drug candidate, and reducing its workforce by 35%.
More negative than 85% of ticker scores this week
A shareholder class action lawsuit has been filed alleging that the company made false statements.
More negative than 76% of ticker scores this week
The company is under investigation by a securities litigation law firm regarding compliance with federal securities laws.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
−58.9%
Price agrees with the score
$0.7313 vs $1.78 close before publication (Jun 12) · not market-adjusted
NMRA chart →
